TABLE 1.
Baseline characteristics of the participants included for analysis of CL001 dose groupsb
| Characteristic | Value for bedaquiline dose groupa |
|||
|---|---|---|---|---|
| 100 mg | 200 mg | 300 mg | 400 mg | |
| No. of participants | 14 | 15 | 14 | 13 |
| No. of male participants (%) | 8 (57) | 11 (73) | 8 (57) | 9 (69) |
| Age (yrs) | 27 (18–48) | 24 (18–61) | 30 (19–47) | 29 (20–58) |
| Body wt (kg) | 53 (41–64) | 53 (41–73) | 50 (44–74) | 51 (40–60) |
| BMI (kg/m2) | 19 (15–24) | 19 (16–23) | 18 (16–27) | 18 (16–24) |
| No. of HIV+ participants (%) | 1 (7) | 1 (7) | 1 (8) | 2 (15) |
| Log10 CFU/mL | 6.31 (4.69–7.51) | 5.77 (4.72–7.47) | 6.33 (3.18–7.82) | 6.70 (4.44–7.66) |
| TTP (days) | 4.23 (2.33–7.08) | 4.57 (2.90–6.81) | 3.96 (2.90–10.20) | 3.56 (3.00–5.42) |
a
Group labels correspond to doses on treatment days 3 to 14. Baseline CFU and TTP values are the averages from two pretreatment measurements. Data are medians (ranges) unless indicated otherwise.
b
BMI, body mass index; HIV+, human immunodeficiency virus positive; TTP, time to positivity.